Lancet, J. E., Cortes, J. E., Hogge, D. E., Tallman, M. S., Kovacsovics, T. J., Damon, L. E., . . . Feldman, E. J. (2014). Phase 2 trial of CPX-351, a fixed 5: 1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood.
Chicago Style CitationLancet, Jeffrey E., et al. "Phase 2 Trial of CPX-351, a Fixed 5: 1 Molar Ratio of Cytarabine/daunorubicin, Vs Cytarabine/daunorubicin in Older Adults With Untreated AML." Blood 2014.
MLA CitationLancet, Jeffrey E., et al. "Phase 2 Trial of CPX-351, a Fixed 5: 1 Molar Ratio of Cytarabine/daunorubicin, Vs Cytarabine/daunorubicin in Older Adults With Untreated AML." Blood 2014.
Warning: These citations may not always be 100% accurate.